CLEC2D and cancer: KLRB1 is involved in the coding of NKRP1A/LLT1, which triggers the activation of T cells and B cells and can be used in the treatment of cancer [36], and its interaction with LLT1 can inhibit natural killing (NK) cell cytotoxicity [37].